Dissociation of locomotor and cerebellar deficits in a murine Angelman syndrome model
Bruinsma, Caroline F; Schonewille, Martijn; Gao, Zhenyu; Aronica, Eleonora M A; Judson, Matthew C; Philpot, Benjamin D; Hoebeek, Freek E; van Woerden, Geeske M; De Zeeuw, Chris I; Elgersma, Ype

published in
Journal of Clinical Investigation
2015

DOI (link to publisher)
10.1172/JCI83541

document version
Publisher's PDF, also known as Version of record

Link to publication in KNAW Research Portal

citation for published version (APA)

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the KNAW public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain.
- You may freely distribute the URL identifying the publication in the KNAW public portal.

Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

E-mail address:
pure@knaw.nl
Dissociation of locomotor and cerebellar deficits in a murine Angelman syndrome model

Caroline F. Bruinsma,1,2 Martijn Schonewille,1 Zhenyu Gao,1 Eleonora M.A. Aronica,3 Matthew C. Judson,4 Benjamin D. Philpot,4 Freek E. Hoebeek,1 Geeske M. van Woerden,1,2 Chris I. De Zeeuw,1,2,5 and Ype Elgersma1,2

1Department of Neuroscience and 1ENCORE Expertise Centre for Neurodevelopmental Disorders, Erasmus MC, Rotterdam, Netherlands. 2Department of (Neuro)Pathology, Academic Medical Center, Amsterdam, Netherlands. 3Department of Cell Biology and Physiology, Neuroscience Center, and Carolina Institute for Developmental Disabilities, University of North Carolina, Chapel Hill, North Carolina, USA. 4Netherlands Institute for Neuroscience, Royal Netherlands Academy of Arts and Sciences, Amsterdam, Netherlands.

Angelman syndrome (AS) is a severe neurological disorder that is associated with prominent movement and balance impairments that are widely considered to be due to defects of cerebellar origin. Here, using the cerebellar-specific vestibulocular reflex (VOR) paradigm, we determined that cerebellar function is only mildly impaired in the Ube3a<sup>m−/m</sup> mouse model of AS. VOR phase-reversal learning was singularly impaired in these animals and correlated with reduced tonic inhibition between Golgi cells and granule cells. Purkinje cell physiology, in contrast, was normal in AS mice as shown by synaptic plasticity and spontaneous firing properties that resembled those of controls. Accordingly, neither VOR phase-reversal learning nor locomotion was impaired following selective deletion of Ube3a in Purkinje cells. However, genetic normalization of αCaMKII inhibitory phosphorylation fully rescued locomotor deficits despite failing to improve cerebellar learning in AS mice, suggesting extracerebellar circuit involvement in locomotor learning. We confirmed this hypothesis through cerebellum-specific reinstatement of Ube3a, which ameliorated cerebellar learning deficits but did not rescue locomotor deficits. This double dissociation of locomotion and cerebellar phenotypes strongly suggests that the locomotor deficits of AS mice do not arise from impaired cerebellar cortex function. Our results provide important insights into the etiology of the motor deficits associated with AS.

Introduction

Angelman syndrome (AS) is a neurological genetic imprinting disorder caused by mutations affecting the maternally inherited UBE3A gene, which encodes the E3A ubiquitin protein ligase (UBE3A or E6-AP). Individuals with AS suffer from severe developmental delay, cognitive deficits, epilepsy, and a lack of speech (1). Individuals with AS also experience problems with movement and balance, an important aspect of the diagnostic criteria described in the original description of the disorder (2). Even in the least severe cases, forward lurching, unsteadiness, jerky motions, and tremulous movement of limbs may manifest (1). The locus of these motor abnormalities is currently unknown, but it is possible that cerebellar dysfunction is a causal factor, given that ataxia and tremor are both common symptoms of cerebellar disorders. In support of this hypothesis, GAB<sub>A</sub> receptors have been shown to be reduced in the cerebellum of patients with AS and in postmortem AS material (3–5). Furthermore, movement studies in patients with AS showed abnormal electromyographic (EMG) rhythmic bursts when maintaining posture (6), which could be indicative of cerebellar dysfunction. However, there has yet to be a rigorous investigation of the putative cerebellar contributions to AS motor phenotypes.

Mice that maternally inherit Ube3a gene deletions (AS mice, referred to herein as Ube3a<sup>m−/m</sup> mice) are a suitable model for studying the origin of motor deficits in AS, as they exhibit globally impaired motor coordination when performing tasks on the accelerating rotarod and balance beam and in bar cross and gait tests (7–12). AS mice exhibit deficits in cerebellar granule and Purkinje cell function that are suggestive of cerebellar dysfunction (13). However, similar to the human behavioral studies, none of these motor tests conducted with mice are specific for cerebellar dysfunction; genetic, anatomic, or pharmacologic lesions in other parts of the brain are known to also affect performance on these type of tasks (14). Moreover, UBE3A is not only highly expressed in the cerebellum, but also in other sensorimotor brain structures such as the cerebral cortex and striatum (7, 8, 15–18). Hence, the observed motor deficits can just as easily arise from circuit dysfunction outside of the cerebellum as from within the cerebellum.

Here, we leveraged conditional Ube3a genetics and cerebellum-specific behavioral tasks to elucidate the extent to which cerebellar dysfunction is responsible for the motor deficits in AS. Despite normal Purkinje cell physiology in AS mice, we found mild cerebellar learning deficits that correlated with reductions in tonic inhibition onto granule cells. However, cerebellar learning deficits proved to be clearly dissociable from locomotor deficits when we reinstated...
UBE3A expression specifically in the cerebellum or following genetic normalization of CaMKII signaling. We therefore conclude that locomotor deficits in AS are most likely not of cerebellar origin.

Results

The cerebellar cortex expresses high levels of UBE3A in Purkinje and Golgi cells. Cell type–specific silencing of the paternal Ube3a allele dictates that UBE3A expression in neurons is solely provided by the maternal Ube3a allele (19–22). To determine whether cerebellar neurons are subject to similar imprinting rules, we performed Western blot analyses of UBE3A protein expression in cerebellar homogenates from WT and AS mice. Consistent with the expected effects of paternal Ube3a imprinting, UBE3A levels in AS cerebella were reduced to 6% ± 5% of levels in WT controls (Figure 1A). To verify that UBE3A is also imprinted in the human cerebellum, we extended our UBE3A Western analyses to samples obtained post-mortem from individuals with AS and neurotypical controls. We found that UBE3A expression in the AS cerebellum was drastically reduced relative to that in controls, confirming that UBE3A expression in the human cerebellum is almost exclusively derived from the maternal allele (Figure 1A).

We next used immunohistochemistry (IHC) to spatially map maternal UBE3A protein expression within the cerebellum. Previous studies documented robust maternal UBE3A expression in Purkinje neurons (7, 8, 13, 15–18), which we also observed (Figure 1B). In addition, consistent with previous observations in maternal Ube3a-YFP reporter mice (17), we observed prominent UBE3A immunoreactivity in a subset of putative GABAergic interneurons within the granule cell layer of WT but not AS mice (Figure 1B). We subsequently confirmed their identity by colocalization with GlyT2-EGFP (Figure 1C), which specifically labels Golgi interneurons within the cerebellar granule cell layer (23). Hence, we conclude that maternal UBE3A expression in the adult cerebellar cortex is enriched in Purkinje and Golgi cells.

AS mice show only mild cerebellar learning deficits. A large body of evidence has shown that cerebellar dysfunction commonly impairs the adaptation of compensatory eye movements (24–27). This adaptation is critically important to stabilize images on the retina and prevent retinal slip. The contribution of the visual and vestibular reflex pathways can be separately quantified by providing either visual stimulation (only the screen is rotating) to elicit a vestibulo-ocular reflex (VOR) (for a visual explanation of these compensatory eye movement paradigms, see the cartoon in Figure 2 and ref. 28). To investigate whether AS mice showed abnormalities in gross cerebellar function, we first measured baseline OKR and VOR performance during sinusoidal visual or turntable stimulation. AS mice showed no deficits (OKR and VOR gain and phase were not different in AS versus WT mice, Table 1). We therefore examined two different paradigms, one involving optokinetic or vestibular stimuli (Figure 2A and B), the other involving optokinetic or vestibular stimuli (Figure 2C and D). AS mice showed no deficits in either paradigm (Table 1), indicating that maternal UBE3A expression in the cerebellar cortex is sufficient to maintain normal locomotor function.

Figure 1. UBE3A is highly expressed in the cerebellum. (A) Western blot analysis revealed high UBE3A expression levels in the cerebellum of mice and humans. Cortical samples of the same protein concentration were used as a reference. UBE3A protein was greatly reduced in AS mice and in AS patients, indicating that UBE3A expression was almost exclusively derived from the maternal allele in cerebellar neurons. The Western blot shown is representative of samples run in duplicate. (B) UBE3A IHC in the cerebellum of WT mice revealed robust labeling of Purkinje cells (in the Purkinje cell layer [PCL]) and sparsely labeled cells within the molecular layer (ML). High expression levels were also observed in sparsely labeled cells in the granule cell layer (GCL) (white arrows), indicative of Golgi cell labeling. (C) UBE3A immunofluorescence (red, middle panel) colocalized with GlyT2-EGFP expression (green, top panel) in sparsely labeled cells in the granule cell layer, identifying them as Golgi cells. Each staining was performed using a minimum of 3 mice. Scale bars: 5 mm (B, top panels), 1 mm (B, bottom left panels), 0.05 mm (B, bottom right panels, and C).
Taken together, these results show that AS mice perform normally on cerebellar tests such as the OKR, VOR, VVOR, and VOR gain-decrease paradigms, but show a striking impairment in the more demanding phase-reversal eye movement task. These results indicate the presence of mild cerebellar deficits in AS mice. Parallel fiber–to–Purkinje cell plasticity is not affected in AS mice.

Plasticity deficits at the parallel fiber (PF) to Purkinje cell synapse can result in cerebellar learning deficits (29). To investigate whether AS mice have impaired PF–Purkinje cell plasticity, we performed whole-cell recordings of Purkinje cells while inducing either long-term potentiation (LTP) via 1 Hz stimulation of PFs or long-term depression (LTD) via 1 Hz paired stimulation of PFs and climbing fibers (CFs). Both LTP and LTD could be readily induced to a similar degree in AS and WT mice (for LTP: AS 126% ± 6.4%, WT 125% ± 5.4%, P = 0.77; for LTD: AS 57% ± 5.3%, WT 64% ± 2.9%, P = 0.26) (Figure 3, A and B). In addition, paired-pulse facilitation (PPF) (with 50 ms between pulses), a measure of neurotransmitter release, was similar between AS and WT mice both before and after LTP/LTD induction (data not shown), making it unlikely that postsynaptic plasticity deficits were masked by pre-
Tonic inhibition of granule cells is reduced in AS mice. As shown in Figure 1, UBE3A is not only prominently expressed in cerebellar Purkinje cells, but also in cerebellar Golgi cells. Golgi cells provide tonic as well as phasic inhibition onto granule cells (36). Tonic and phasic inhibition are mediated by extrasynaptic, α6-containing GABA_A receptors and synaptic, γ2-containing GABA_A receptors, respectively (for review see ref. 29). Tonic inhibition of granule cells in AS mice has been shown to be impaired, perhaps due to hyperfunctional GAT1-mediated reductions in available extrasynaptic GABA (37). To confirm these findings in our AS mice, we recorded both tonic and phasic inhibition in granule cells dialyzed with a high-chloride internal solution at −70 mV. Mean tonic inhibition of AS granule cells (−17.1 ± 2.6 pA) was significantly lower than that of WT controls (−33.1 ± 5.6 pA; t_{39} = −2.7, P < 0.01) (Figure 4A). In contrast, phasic inhibition was not affected, as the frequency, amplitude, and kinetics of spontaneously occurring inhibitory postsynaptic currents (sIPSCs) in AS granule cells were comparable to that observed in WT mice (all P > 0.5) (Figure 4B). These data confirm that tonic but not phasic inhibition between Golgi cells and granule cells is selectively impaired in AS mice. Since the current behavioral phenotype in AS mice closely resembles the deficits of mouse mutants in which granule cell inhibition is specifically manipulated (38), we hypothesize that tonic Golgi cell inhibition of cerebellar granule cells may contribute to the cerebellar phase-reversal learning deficit of AS mice.

UBE3A expression in Purkinje cells is dispensable for normal cerebellar learning and locomotion. Given our collective observations in AS mice with normal Purkinje cell physiology (Figure 3) and mild cerebellar learning deficits (Figure 2), which may be linked to impaired tonic granule cell inhibition (38), we hypothesized that selective loss of UBE3A expression in Purkinje cells would contribute to neither cerebellar learning nor locomotor deficits. To investigate this, we deleted the maternal Ube3a gene specifically...
in Purkinje cells by crossing female floxed Ube3a mice with male mice expressing Cre recombinase from the L7 promoter (39). The resultant Ube3a<sup>fl/+</sup> L7-Cre mice exhibited a selective loss of UBE3A in Purkinje neurons relative to WT (Ube3a<sup>wt/+</sup> L7-Cre) controls, whereas expression in cerebellar Golgi cells remained intact (Figure 5A). We then tested whether Purkinje cell–specific deletion of UBE3A affected normal VOR phase-reversal learning. Notably, Ube3a<sup>fl/+</sup> L7-Cre mice showed normal VOR phase-reversal learning and retained the ability to consolidate the learned response overnight (all P > 0.05), indicating that Purkinje cell–specific UBE3A loss does not affect cerebellar learning (Figure 5, C and D).

To test whether loss of UBE3A expression in Purkinje cells is responsible for the locomotor deficits, we tested Ube3a<sup>fl/+</sup> L7-Cre mutant mice on the accelerating rotarod, which has reliably revealed gross motor coordination deficits in AS mice (7–12). Consistent with the observation that UBE3A expression in Purkinje cells is not required for normal cerebellar learning, we observed no significant deficit in locomotor performance in the rotarod test (repeated-measures ANOVA F<sub>1,21</sub> = 0.7, P = 0.8; Figure 5B). Hence, loss of UBE3A expression in Purkinje cells is not sufficient to cause the cerebellar and locomotor deficits observed in AS mice.

Normalization of αCaMKII inhibition rescues locomotor but not cerebellar learning deficits in AS mice. CaMKII activity is markedly reduced in AS mice, presumably due to increased inhibitory phosphorylation of αCaMKII at Thr305/Thr306 (40). Accordingly, normalizing CaMKII inhibition in AS mice by mutating the Thr305/Thr306 phosphorylation sites of the CaMK2A gene, thereby preventing autophosphorylation at αCaMKII Thr305 and Thr306 (41), fully restores certain capabilities, including locomotor performance (9). In the cerebellum, αCaMKII is exclusively expressed in Purkinje cells and is essential for Purkinje cell plasticity and cerebellar learning (42). Given our results showing that UBE3A expression in Purkinje cells is not required for normal cerebellar and locomotor learning, we hypothesized that introducing the αCaMKII-T305V/T306A mutation in AS mice would rescue the locomotor but not the cerebellar learning deficits. Hence, we crossed female AS (Ube3a<sup>wt/−</sup>) mutants with male heterozygous αCaMKII-TT305/6VA mutants (referred to hereafter as CaMKII-305/6VA mice). This crossing resulted in 4 genotypes (WT, AS mutants, heterozygous CaMKII-305/6VA mutants, and AS/CaMKII-305/6VA double mutants). We replicated our previous findings (43) that the AS motor deficit seen on the accelerating rotarod is rescued in the AS/CaMKII-305/6VA double mutant (repeated-measures ANOVA on genotype F<sub>3,30</sub> = 13; P < 0.0001), with only AS mice showing a significant deficit in rotarod performance compared with WT mice (Figure 6A).

To investigate whether reduction of αCaMKII inhibition also rescued cerebellar function, we measured baseline OKR, VOR, and VVOR performance in the AS/CaMKII-305/6VA double mutants and control mice. Like the AS mutation, neither the CaMKII-305/6VA nor the AS/CaMKII-305/6VA double mutation affected the baseline amplitude (gain) or timing (phase) of either the optokinetic or vestibular reflex. However, whereas the AS mice again showed a clear deficit in the VOR phase-reversal paradigm, this deficit was not rescued in the AS/CaMKII-305/6VA double mutants (Figure 6B and C). These results indicate that the molecular mechanism that underlies the VOR phase-reversal deficit is distinct from the mechanism that underlies the locomotor impairment.

Reinstatement of UBE3A expression in the cerebellum rescues cerebellar learning but not locomotor impairments. Rescue of rotarod performance in AS/CaMKII-305/6VA double mutant mice could be due to normalization of function in extracerebellar motor circuits with enriched CaMKII expression, such as in the cortex or striatum. Alternatively, gain of function in Purkinje neurons could also conceivably explain the rescue, however, this is unlikely. To further challenge the assertion of cerebellar involvement in AS motor deficits, we used Ube3a<sup>fl/+</sup> Cre<sup>ERT2</sup> mice (44), which, in the absence of the Cre-ERT2–activating drug tamoxifen, express UBE3A at AS levels in the forebrain due to the presence of a floxed stop cassette that inhibits transcriptional read-through of the Ube3a<sup>wt</sup> allele. In the cerebellum, however, this inducible gene regulation system is
Locomotor deficits in Ube3aStop/p+ CreERT+

learning, as Ube3aStop/p+ CreERT+
of UBE3A expression proved sufficient to support normal cerebellar
of rescue by cerebellar UBE3A reinstatement. In contrast, this level
from Purkinje cells does not affect cerebellar learning or locomotion.

**Discussion**

Patients with AS show various severities of motor deficits such as an ataxic-like gait, forward lurching, unsteadiness, clumsiness, jerky

motions, and/or tremulous movement of limbs (1). The AS mouse model appears to be a suitable model for studying the motor deficits in AS, as it exhibits globally impaired motor coordination in a variety of tasks such as accelerating rotarod, balance beam, bar cross, and gait tests (7–12).

The idea that cerebellar deficits underlie the movement deficits in individuals with AS has been dogmatic since the original publication describing AS (2). Given that Purkinje cells provide the sole output of the cerebellar cortex and that these cells express high levels of UBE3A, it is also not surprising that deficient Purkinje cell function is generally believed to underlie the locomotor deficits in AS mice and in patients with AS (13). Our results in AS mice overturn both of these dogmas. First, although we show that the Ube3a gene is highly expressed in cerebellar Golgi and Purkinje cells and that this expression is almost exclusively derived from the maternal allele, we found that cerebellar deficits of AS mice were rather mild and were only observed with an extremely demanding cerebellar task. Second, we observed none of the changes in Purkinje cell physiology (synaptic plasticity, action potential firing) that typically correlate with cerebellar learning impairments (29). Third, we show that deletion of Ube3a from Purkinje cells does not affect cerebellar learning or locomotion. And last, we used several mouse models to demonstrate a double dissociation between locomotor function and cerebellar learning, which strongly argues against cerebellar dysfunction being the underlying reason for the locomotor deficits.

Consistent with previous findings (37) and the potent tonic inhibition of granule cell activity by Golgi cell inhibition, we observed impaired tonic inhibition of granule cells by Golgi cells in AS mice. The moderate behavioral cerebellar phenotype in AS mice is in line with impaired granule cell inhibition, as similar phenotypes have been observed in other mouse models in which the granule cell network is specifically disrupted (ref. 45 and for review
These findings suggest that defective Golgi cell functioning might be involved in learning, while their OKR, VOR, and VVOR basic motor performance was not impaired. We then addressed the issue of which brain regions contribute to the prominent deficits in AS mice. To achieve this, we generated mice with a granule cell–specific mutation in the cotransporter gene; this genetic manipulation depolarizes granule cells by increasing their cytosolic chloride concentration. Like AS mice, these mutants also show severely impaired phase-reversal learning, while their OKR, VOR, and VVOR basic motor performance and gain-decrease learning are unaffected. Together, these findings suggest that the cerebellar cortex plays no role at all and that these deficits arise instead from deficits in the cerebellar nuclei.

It seems unlikely that the impaired tonic inhibition of Golgi cells onto granule cells underlies the locomotor deficits in AS mice, as ablation of cerebellar Golgi cells causes only a transient ataxia (46). Instead, the locomotor and cerebellar VOR phase-reversal deficits are likely regulated by distinct mechanisms. A hypothesis supported by our measurements of the AS/CaMKII-305/6VA double mutant is that there is a double dissociation between cerebellar deficits and those arising from impaired CaMKII signaling in the nigrostriatal pathway (47). Specifically, AS mice exhibited changes in dopamine release in both mesolimbic and nigrostriatal pathways (47), whereas another study reported increased dopamine levels in the striatum, midbrain, and frontal cortex of AS mice (48). AS mice were also shown to have a reduced number of tyrosine hydroxylase–positive neurons in the substantia nigra (10). Interestingly, CaMKII phosphorylation is increased in the striatum of AS mutant mice (10), and CaMKII has been shown to be a regulator of the dopamine transporter and the dopamine D3 receptor (49–51). Collectively, these findings indicate that impaired CaMKII/dopamine signaling in the nigrostriatal pathway is a possible mechanism underlying the AS motor pathophysiology. This issue remains to be addressed in future studies.

In conclusion, we show here that AS mice have rather mild cerebellar deficits and that these deficits are likely caused by the impaired tonic inhibition of granule cells rather than by Purkinje cell dysfunction. Moreover, we show through genetic manipulations that there is a double dissociation between cerebellar deficits and locomotor deficits, such that we can correct locomotor learning without rescuing cerebellar learning, and vice versa. These results strongly suggest that the cerebellar cortex plays a minor role at best in the pronounced motor performance deficits observed in AS mice.

**Methods**

**Mice.** Mutant mice harboring the Ube3a-null mutation (referred to herein as AS mice) and mutants heterozygous for the targeted αCaMKII-T305V/T306A mutation, which prevents phosphorylation at these residues (referred to herein as CaMKII-305/6VA mice), were developed as described previously (7, 9, 41). Mutant Ube3a<sup>tm1<sup>Pp</sup></sup> mice were generated at the University of North Carolina Animal Models Core facility by using the
Ube3a\textsuperscript{Kisla} targeting construct (CSD46841; clone PG00126_Z_3_B08 Al), generated by the trans-NIH Knockout Mouse Project (KOMP; www.komp.org). Targeted C57BL/6N-tac mouse embryonic stem cells (PRX-B6N 1; Primogenix) were used to derive chimeric Ube3a\textsuperscript{Kisla} males, which were crossed with C57BL/6 Rosa26-FLPe mice (009086; The Jackson Laboratory) to excise the FRT-flanked lacZ gene trap from the Ube3a\textsuperscript{Kisla} allele, resulting in the conditional Ube3a floxed allele (Ube3a\textsuperscript{fl}). The FLPe allele was eliminated by further crossing the mice on a congenic C57BL/6 background (000664; The Jackson Laboratory) to excise the FRT-flanked lacZ gene trap from the Ube3a\textsuperscript{fl} allele, resulting in the conditional Ube3a floxed allele (Ube3a\textsuperscript{fl}). The FLPe allele was eliminated by further crossing the mice on a congenic C57BL/6 background (000664; The Jackson Laboratory) to excise the FRT-flanked lacZ gene trap from the Ube3a\textsuperscript{fl} allele, resulting in the conditional Ube3a floxed allele (Ube3a\textsuperscript{fl}).

For DAB staining, brains were fixed with 4% paraformaldehyde by transcardial perfusion, as described above. Immunocytochemistry was performed on free-floating 40-μm frozen sections using a standard avidin-biotin-immunoperoxidase complex (ABC) method (Vector Laboratories) with anti-E6AP (1:1,000; clone E6AP-330; Sigma-Aldrich) as the primary antibody and rabbit anti-mouse HRP as the secondary antibody (1:200; ALG P0260; Dako), followed by DAB staining.

**Western blot analysis.** For measurement of UBE3A protein expression, mice were sacrificed by cervical dislocation, and the cerebellum was snap-frozen in liquid nitrogen. Human temporal cortex tissue was obtained from the National Institute of Child Health and Human Development (NICHD) Brain and Tissue Bank for Developmental Disorders. The tissues were homogenized in a lysis buffer containing 10 mM Tris-HCl (pH 6.8), 2.5% SDS, 2 mM EDTA, and a protease and phosphatase inhibitor cocktail (Sigma-Aldrich). Fifteen micrograms of protein was used for Western blot analyses. The Western blots were probed with an antibody against UBE3A (1:1,000; clone E6AP-330; Sigma-Aldrich) as the primary antibody and rabbit anti-mouse HRP as the secondary antibody (1:200; ALG P0260; Dako), followed by DAB staining.
Rotarod. Motor coordination of 3- to 4-month-old mutant mice and their WT littermates was tested on an accelerating rotarod (model 7650, Ugo Basile; Biological Research Apparatus). Performance was determined as the average of 2 trials with an inter-training interval of 1 hour. This was repeated for 2 to 5 days. The rotarod has a cylinder with a diameter of 3 cm that can accelerate from 4 to 40 rpm in 300 seconds. The latency to stay on the rotarod was recorded by determining the time taken for a mouse to drop off or stop running for 3 consecutive rotations.

Eye movement recordings. Compensatory eye movements were recorded as described before (28). In short, mice were anesthetized, and an immobilizing construction containing 2 attached nuts (3 mm each) was placed on the frontal and parietal bones using OptiBond primer and adhesive (Kerr) and Charisma (Heraeus Kulzer). After 5 days of recovery, mice were head fixed and placed in a restrainer in the middle of a turntable surrounded by a cylindrical screen (with a diameter of 60 and 63 cm, respectively). After a habituation session, baseline OKR, VOR, and VVOR were evoked by rotating the screen and/or table (5° amplitude, 0.1–1.0 Hz frequency). The next day, mice were subjected to five 10-minute periods of sinusoidal in-phase screen and table rotations (both at 5° amplitude, 0.6 Hz) aimed at decreasing the gain of the VOR. On the subsequent days, the VOR was phase reversed by five 10-minute periods of in-phase table and screen rotations at 0.6 Hz, with screen amplitudes varying from 7.5° (day 2) to 10° (days 3 and 4). Mice were kept in the dark between training days to prevent active extinction. Before, between, and at the end of each training session, the VOR was measured. Mice used for eye movement recordings were littermates between 3 and 6 months of age (average age of 21 weeks for WT mice, 22 weeks for AS mice, 24 weeks for CaMKII-305/6VA mice, and 23 weeks for CaMKII-305/6VA AS mutants; not statistically different; 1-way ANOVA $F_{1,22} = 9.2, P = 0.6$). The eye movements were recorded at 240 Hz using a CCD camera fixed to the table, and pupil position was obtained using an eye-tracking system (ISCAN). Video calibrations and subsequent eye movement computations were performed with custom-made MATLAB (MathWorks) routines, as described previously (33). To analyze compensatory eye movements, phase and gain were calculated by fitting a sine function to the averaged eye and stimulus velocity traces. Gain was calculated as the ratio of eye-to-stimulus velocity traces. Phase was computed as the difference in degrees between the eye and the stimulus velocity.

In vitro electrophysiology. For in vitro recordings of Purkinje cells, cerebellar slices were prepared according to a standardized protocol to allow recordings of long-term synaptic plasticity at the PF-Purkinje cell synapse (43). Slices of the cerebellar vermis (250 μm) from 10- to 30-week-old mice were obtained by decapitation after isoflurane anesthesia. Slices were cut in ice-cold oxygenated (with 95% O₂ and 5% CO₂) solution containing 124 mM NaCl, 5 mM KCl, 1.25 mM Na₂HPO₄, 2 mM MgSO₄, 1 mM CaCl₂, 26 mM NaHCO₃, and 10 mM D-glucose. Next, slices were transferred to a submerged room-temperature holding chamber with artificial cerebral spinal fluid (ACSF) containing 150 mM CsCl, 15 mM CsOH, 1.5 mM MgCl₂, 0.5 mM EGTA, 10 mM HEPES, 4 mM Na ATP, and 0.4 mM NaGTP (pH 7.3). Recordings were performed at 34°C using standard ACSF supplemented with 10 μM NBQX and 10 μM D-AP5. Granule cells were held at ~70 mV (without junction potential correction) in voltage clamp configuration. Recordings during which the initial holding current increased over ~100 pA and/or the series resistance increased over 25 MΩ were excluded from analysis. The tonic GABAₐ receptor–mediated current was measured by comparing the difference in holding current recorded in the presence and absence of 10 mM picrotoxin. sIPSCs were detected using the Mini Analysis program (Synaptosoft). Cutoff amplitudes for IPSC detection were set at 6 to 8 pA. All selected IPSCs were visually inspected. Averaged IPSC waveforms were constructed exclusively from nonoverlapping events. The decay time was calculated as the time from the peak to 37% of the peak amplitude.

In vivo electrophysiology. A craniotomy of 2 mm was made in the left occipital bone, and a recording chamber was placed around it, allowing chronic in vivo electrophysiological recordings (52). Mice were head fixed, and extracellular Purkinje cell activity was recorded and analyzed as previously described (53). Purkinje cells were identified by the firing of complex spikes and were confirmed to be from a single unit by the presence of a pause of at least 5 ms in simple spike firing after each complex spike. The recordings were processed by a custom-made MATLAB routine based on principal component analysis. For each cell, the mean firing rate and coefficients of variation (CV and CV2) were determined for simple and complex spikes. CV is a measure of the reg-
ularity of spiking during the entire recording period and is calculated by dividing the standard deviation by the mean of all interspike intervals in a given recording; CV2 is a measure of the regularity on a spike-to-spike basis and is calculated as the mean of 2 times the difference between 2 consecutive interspike intervals (ISIs) divided by the sum of the 2 intervals, i.e., \(\sqrt{2(\text{ISI}_{n+1} - \text{ISI}_n)/(\text{ISI}_{n+1} + \text{ISI}_n)})\).

**Statistics.** For the consolidation measurement, a 1-way ANOVA test was used, followed when significant, by a post-hoc Bonferroni test. Student’s 2-tailed t tests were used for group comparisons of a single variable (e.g., protein levels, LTP, and LTD). A repeated-measures ANOVA with genotype as the between-subjects factor and frequency or time as the within-subjects factor was used to assess group differences in the eye movement recordings. Genotypic differences were probed with post-hoc Bonferroni comparisons. For all analyses, a P value of less than 0.05 was considered significant.

**Study approval.** All animal experiments were approved by the Dutch Dierexperimenten commissie (DEC) ethics committee and were performed in accordance with Dutch animal care and use laws.

**Author contributions**

CFB, CZ, and YE designed the research studies; CFB, GMW, and ZG conducted the experiments; EMAA provided human samples; BDP and MCJ generated the floxed UBE3A mouse; CFB, FEH, MS, and ZG analyzed the data. All authors had significant input in the scientific discussions and writing of the manuscript.

**Acknowledgments**

We thank M. Elgersma, M. Aghadavoud, L. Post, R. de Avila Freire, J. Harkonen, E. Galliano, and E. Goedknegt for their technical assistance. This work was supported by grants from the Nina Foundation (to C.F. Bruinsma); the Associazione Angelman Onlus (to Y. Elgersma); and the Dutch Organization for Medical Sciences (ZonMw; to C.I. De Zeeuw and Y. Elgersma); Earth and Life Sciences (ALW, to M. Schonewille, F.E. Hoebeek, and C.I. De Zeeuw). Support was also provided by Erasmus University fellowships (to G.M. van Woerden, M. Schonewille, and F.E. Hoebeek); Senter (NeuroBasic, to C.I. De Zeeuw and Y. Elgersma); European Research Council (ERC) Advanced Grants (to C.I. De Zeeuw); the Angelman Syndrome Foundation (ASF) (to B.D. Philpot and Y. Elgersma); the Simons Foundation (SFARI 274426, to B.D. Philpot and 275234, to Y. Elgersma); the NIH (RO1NS085093, to B.D. Philpot and F32NS077686, to M.C. Judson); and the National Association for Research on Schizophrenia and Depression (NARSAD) (to M.C. Judson). Human cerebral and cerebellar tissue was obtained from the NICHD Brain and Tissue Bank for Developmental Disorders of the University of Maryland.

Address correspondence to: Chris I. De Zeeuw or Ype Elgersma, Department of Neuroscience, Erasmus MC, Wytemaweg 80, 3015 CN, Netherlands. E-mail: y.elgersma@erasasmusmc.nl (Y. Elgersma), c.dezeeuw@erasasmusmc.nl (C.I. De Zeeuw).


